US President Donald Trump has made falling prescription drug prices the cornerstone of the Republican Party's midterm election campaign, asserting that his most-favoured-nation (MFN) pricing policy has produced the largest pharmaceutical cost reductions in American history. Trump made the claim during a political address in Garden City, New York, on 15 August.

What Trump Claimed

Speaking to supporters, Trump said his MFN policy had driven price differences of '400, 500 and even 600 percent' compared to previous levels. He also cited morning newspaper headlines, stating: 'The headline in most of the papers this morning was the largest drug price decrease in 65 years.'

Trump further claimed that the United States had shifted from paying the world's highest prescription drug prices to its lowest — a sweeping assertion he did not back with itemised data. He did not specify which medicines were covered by the reductions or provide before-and-after figures for patient costs.

The Tariff Lever

Trump said his administration secured the reductions by pressuring other countries to accept higher drug prices in their own markets, using the threat of tariffs as leverage. 'If they weren't going to do it, I said, I'm going to raise tariffs on you. I'm going to put 100 percent tariff, it's going to be 10 times more,' he said. He added that foreign nations had to 'double their prices' to enable American reductions — a mechanism critics have noted shifts costs rather than eliminates them.

The Midterm Calculation

Trump framed the drug pricing issue as a potential election-winner in its own right. 'That alone should win us the midterms, really, that alone because that reduces health care, reduces everything,' he said, repeating the line twice during his address. The remarks came as part of a wider political speech covering crime, immigration, Iran, and the economy, in which Trump urged voters to back Republican congressional candidates and warned that Democratic policies would raise costs and weaken public safety.

What Is Missing From the Claim

Notably, Trump's address did not include an independent breakdown of the savings, the list of drugs affected, or verification from health agencies. The MFN policy — which ties US drug prices to the lowest price paid by comparable nations — has faced legal challenges and implementation questions since it was first proposed. Whether the reductions cited represent broad market impact or selected categories remains unclear from the president's remarks.

What Comes Next

With the congressional midterm elections approaching, the Republican Party is expected to lean heavily on the healthcare cost narrative. Analysts will watch whether the drug pricing claim holds up to independent scrutiny and whether Democratic candidates mount a detailed counter-argument on coverage and access — areas where MFN critics argue the policy falls short.